These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 26589495)
21. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Eyre TA; Roeker LE; Fox CP; Gohill SH; Walewska R; Walter HS; Forconi F; Broom A; Arumainathan A; Brander DM; Allan JN; Schuster SJ; Hill BT; Lansigan F; Cheson BD; Lamanna N; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Pearson L; Pagel JM; Jacobs R; Mato AR Br J Haematol; 2020 Mar; 188(6):918-923. PubMed ID: 31682002 [TBL] [Abstract][Full Text] [Related]
22. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541 [TBL] [Abstract][Full Text] [Related]
23. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Lampson BL; Davids MS Curr Hematol Malig Rep; 2017 Feb; 12(1):11-19. PubMed ID: 28116634 [TBL] [Abstract][Full Text] [Related]
24. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474 [TBL] [Abstract][Full Text] [Related]
25. Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy. Li X; Dou J; You Q; Jiang Z Eur J Med Chem; 2021 Aug; 220():113539. PubMed ID: 34034128 [TBL] [Abstract][Full Text] [Related]
26. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner. Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423 [TBL] [Abstract][Full Text] [Related]
27. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374 [TBL] [Abstract][Full Text] [Related]
28. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond. Choi JH; Bogenberger JM; Tibes R Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019 [TBL] [Abstract][Full Text] [Related]
29. Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models. Nguyen TH; Koneru B; Wei SJ; Chen WH; Makena MR; Urias E; Kang MH; Reynolds CP Mol Cancer Ther; 2019 Dec; 18(12):2270-2282. PubMed ID: 31484706 [TBL] [Abstract][Full Text] [Related]
30. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706 [TBL] [Abstract][Full Text] [Related]
31. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment. Moia R; Diop F; Favini C; Kodipad AA; Gaidano G Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706 [TBL] [Abstract][Full Text] [Related]
32. Venetoclax: Targeting BCL2 in Hematological Cancers. Scheffold A; Jebaraj BMC; Stilgenbauer S Recent Results Cancer Res; 2018; 212():215-242. PubMed ID: 30069633 [TBL] [Abstract][Full Text] [Related]
33. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Ng SY; Davids MS Clin Adv Hematol Oncol; 2014 Apr; 12(4):224-9. PubMed ID: 25003352 [TBL] [Abstract][Full Text] [Related]
34. Pioneering apoptosis-targeted cancer drug poised for FDA approval. Mullard A Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080 [No Abstract] [Full Text] [Related]
35. [Research Progress of Oral BCL-2 Inhibitor Venetoclax in the Treatment of Non-Hodgkin's Lymphoma --Review]. Guo MQ; Luo XY; Wu HY; Huang YX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1622-1626. PubMed ID: 36208277 [TBL] [Abstract][Full Text] [Related]
36. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580 [TBL] [Abstract][Full Text] [Related]